Patent Term Adjustment (PTA) was designed to serve an important purpose – to compensate patentees for time lost during examination due to U.S. Patent and Trademark Office (USPTO) delays. Most industries rely heavily on their patent portfolios to drive business strategies that ultimately impact their bottom line. The impact of patent term is especially acute in the pharmaceutical and biotechnology industries, where companies spend billions of dollars to develop new drugs. For these companies, every day that their patent is in force matters, generating millions in additional revenue. With so much at stake, companies strive to accrue all the patent term they are entitled to under the current statutory regime, including by way of PTA.
Recent Posts
- Patent Eligibility Reform Returns to the Hill: PERA 2025 Explained
- PayPal, Apple Succeed in Scrapping Fintiv’s Patent Claims at CAFC
- CAFC Affirms TTAB’s Genericness Test for Color Marks
- AI and the Law: How Companies Can Navigate IP Risk and Seize Opportunity | IPWatchdog Unleashed
- Press Play on American IP: AI Can’t Scratch the Soundtrack to World IP Day